ReviewProtein & cell2023
"Sentinel or accomplice": gut microbiota and microglia crosstalk in disorders of gut-brain interaction.
Review in Protein & cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Sex-specific gut microbiota and metabolite signatures in Parkinson's disease: implications for personalized therapeutics.Metabolic brain disease · 2026Review
- Dynamic gut microbiota shift in chronic liver disease progression: machine learning models and the E/Er ratio as a predictive biomarker.Journal of translational medicine · 2026Article
- Phocaeicola vulgatus improves anxiety-like behavior by ameliorating amygdala neuroinflammation and the neurite impairment in IBS.Translational psychiatry · 2026Article
- Gastrointestinal dysfunction after brain injury: Mechanisms and the role of the brain-gut axis.World journal of gastroenterology · 2026Review
- Akkermansia muciniphila vesicles attenuate smoking-induced cognitive decline via ILA-mediated AhR-dependent microglial reprogramming.Journal of nanobiotechnology · 2026Article
- Bidirectional interactions along the microbiota-gut-brain axis in radiation-induced brain injury: mechanisms and therapeutic insights.Frontiers in oncology · 2026Review
- Mechanism of Microbiota-Gut-Brain in Perimenopausal Depression: An Inflammatory Perspective.Expert reviews in molecular medicine · 2025Review
- Lactoferrin alleviates the adverse effects of early-life inflammation on depression in adults by regulating the activation of microglia.Molecular medicine (Cambridge, Mass.) · 2025Article
- Review of research progress on intestinal microbiota based on metabolism and inflammation for depression.Archives of microbiology · 2024Review
- Effect of Tryptophan Restriction in the Therapy of Irritable Bowel Syndrome: a Systematic Review.International journal of general medicine · 2024Review
- A long journey to treat epilepsy with the gut microbiota.Frontiers in cellular neuroscience · 2024Review
- Microbiome research outlook: past, present, and future.Protein & cell · 2023Article
- Multidirectional associations between the gut microbiota and Parkinson's disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Abnormal brain-gut interaction is considered the core pathological mechanism behind the disorders of gut-brain interaction (DGBI), in which the intestinal microbiota plays an important role. Microglia are the "sentinels" of the central nervous system (CNS), which participate in tissue damage caused by traumatic brain injury, resist central infection and participate in neurogenesis, and are involved in the occurrence of various neurological diseases. With in-depth research on DGBI, we could find an interaction between the intestinal microbiota and microglia and that they are jointly involved in the occurrence of DGBI, especially in individuals with comorbidities of mental disorders, such as irritable bowel syndrome (IBS). This bidirectional regulation of microbiota and microglia provides a new direction for the treatment of DGBI. In this review, we focus on the role and underlying mechanism of the interaction between gut microbiota and microglia in DGBI, especially IBS, and the corresponding clinical application prospects and highlight its potential to treat DGBI in individuals with psychiatric comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.